Redeye's Q4 comment is that the US DiviTum approval is on track and that additional supporting clinical trials are progressing. Biovica also confirms that the company is in advanced discussions that it is likely to secure a strategic partner supporting DiviTum's US launch. We do not expect any specific significant Q4 share price reaction. Our value proposition is a base case value of SEK 95 (Bull SEK 325 and Bear SEK 20).